UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report:
(Date of earliest event reported)
(Exact name of Registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
| (Address of principal executive offices, including zip code) |
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading symbols |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On November 4, 2020, the Board of Directors (the “Board”) of Tenet Healthcare Corporation (the “Company”) appointed the Company’s President and Chief Operating Officer, Saum Sutaria, M.D., to the Board effective immediately. The size of the Board increased from ten to eleven directors upon the effectiveness of Dr. Sutaria’s appointment. Dr. Sutaria’s initial term will expire concurrently with the terms of the other members of the Board, and Board members will stand for annual election at the Company’s 2021 Annual Meeting of Shareholders. Dr. Sutaria will not serve on any committee of the Board.
As an executive officer of the Company, Dr. Sutaria will not receive compensation for his service on the Board. Dr. Sutaria is not party to any material plan, contract, or arrangement with the Company other than those related to his compensation as described in the Company’s proxy statement filed with the Securities and Exchange Commission on April 17, 2020. There are no arrangements or understandings pursuant to which Dr. Sutaria was appointed to the Board, and Dr. Sutaria is not a party to any transaction with the Company reportable under Item 404(a) of Regulation S-K under the Securities Act of 1933.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TENET HEALTHCARE CORPORATION | ||||||
| Date: November 6, 2020 | ||||||
| By: | /s/ Audrey Andrews | |||||
| Name: | Audrey Andrews | |||||
| Title: | Executive Vice President, General Counsel and Corporate Secretary | |||||